EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Pentosan polysulfate sodium for chronic bladder pain conditions: Real-world experiences from a tertiary care center

Dayan Jacob, George Hanna, Ahmed Ghonaimy, Sumathi Gelli, Emma Pattie, Wasim Mahmalji, Mehwash Nadeem

Bladder · 2025

DOI: 10.14440/bladder.0247 ↗
AstrattDettalji biblijografiċi

Astratt

Background: Bladder pain syndrome (BPS) is a chronic condition characterized by pelvic pain and lower urinary tract symptoms. Pentosan polysulfate sodium (PPS) is the only oral therapy licensed in the United Kingdom (UK) for BPS; however, evidence on its effectiveness is inconsistent, with limited data for off-label use in ketamine- or radiation-induced cystitis. Objective: This study evaluates real-world outcomes of PPS in patients with BPS and other chronic bladder pain at a UK tertiary center. Methods: A retrospective review included 42 patients prescribed PPS between 2020 and 2024 for BPS (n = 29), ketamine-induced cystitis (n = 9), or radiation/chemotherapy-induced cystitis (n = 4), excluding Bacillus Calmette–Guérin cystitis. Demographics, comorbidities, prior treatments, symptom severity, and treatment response were recorded. Changes in quality of life (QoL) and Interstitial Cystitis Symptom Index/Interstitial Cystitis Problem Index (ICSI/ICPI) scores were analyzed using the Wilcoxon signed-rank test and one-way analysis of variance. Results: The mean age was 49.7 years, and 81% were female, with a median follow-up of 15.3 months. All patients were severely symptomatic at baseline. Among those with follow-up data, 42.5% were asymptomatic, 25% mildly symptomatic, and 32.5% remained severely symptomatic. QoL improved significantly (Wilcoxon Z = −4.71, p

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →